5 citations
,
May 2018 in “European journal of pharmacology” This study reviewed the pharmacological properties of fesoterodine and found that its ability to effectively treat overactive bladder, especially in the elderly, is likely due to its specific properties, including its receptor affinity, blood-brain barrier penetration, metabolic conversion, and extended-release formulation.
1 citations
,
March 2009 in “The Journal of Urology” This review discusses trials on therapies for benign prostatic hyperplasia and reports that combination treatment is more effective than monotherapy for symptom relief and slowing disease progression in men with moderate to severe symptoms and enlarged prostate glands.
October 2015 in “Annals of Internal Medicine” Dutasteride, fesoterodine, and finasteride help older patients with urinary issues.
111 citations
,
June 2015 in “Age and Ageing” This study classified dutasteride, fesoterodine, and finasteride as beneficial for older or frail elderly patients, while suggesting caution or avoidance of α-blockers and antimuscarinics in this group.
2 citations
,
November 2019 in “Current Geriatrics Reports” Tailored treatment is crucial for elderly men with BPH due to potential risks and benefits of medications.